Daniel Vitt Acquires 15,000 Shares of Immunic, Inc. (NASDAQ:IMUX) Stock

Immunic, Inc. (NASDAQ:IMUX) CEO Daniel Vitt purchased 15,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 4th. The stock was bought at an average price of $0.77 per share, for a total transaction of $11,550.00. Following the purchase, the chief executive officer now owns 29,000 shares in the company, valued at $22,330. The trade was a 107.14% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this link.

Immunic Price Performance

Shares of IMUX opened at $0.79 on Friday. The firm has a 50 day simple moving average of $0.96 and a two-hundred day simple moving average of $1.05. Immunic, Inc. has a one year low of $0.56 and a one year high of $2.11. The company has a market cap of $75.54 million, a P/E ratio of -0.64 and a beta of 1.73.

Immunic (NASDAQ:IMUX) last released its quarterly earnings data on Thursday, May 15th. The company reported ($0.25) earnings per share for the quarter, meeting the consensus estimate of ($0.25). On average, analysts expect that Immunic, Inc. will post -0.94 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Wall Street Zen cut Immunic from a “hold” rating to a “sell” rating in a report on Thursday, March 20th. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price target on shares of Immunic in a research report on Thursday. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Immunic in a report on Thursday, May 1st. William Blair reiterated an “outperform” rating on shares of Immunic in a research report on Friday, May 16th. Finally, B. Riley reissued a “buy” rating and set a $5.00 price target (down previously from $6.00) on shares of Immunic in a research report on Friday, May 23rd. One analyst has rated the stock with a sell rating, six have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, Immunic has an average rating of “Buy” and a consensus price target of $11.60.

Institutional Investors Weigh In On Immunic

Hedge funds have recently made changes to their positions in the stock. 683 Capital Management LLC grew its stake in shares of Immunic by 2.2% during the fourth quarter. 683 Capital Management LLC now owns 700,000 shares of the company’s stock worth $700,000 after buying an additional 15,349 shares during the last quarter. Bridgeway Capital Management LLC raised its position in Immunic by 11.5% in the fourth quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company’s stock valued at $215,000 after purchasing an additional 22,200 shares during the last quarter. Focus Partners Wealth boosted its stake in shares of Immunic by 1.1% during the fourth quarter. Focus Partners Wealth now owns 2,168,353 shares of the company’s stock valued at $2,168,000 after purchasing an additional 23,610 shares in the last quarter. Invesco Ltd. bought a new stake in shares of Immunic during the fourth quarter worth about $37,000. Finally, Barclays PLC acquired a new position in shares of Immunic in the fourth quarter valued at approximately $84,000. 51.82% of the stock is currently owned by institutional investors and hedge funds.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.